10.95

3.44% -0.39

After Hours: 10.78 -0.17 -1.55%

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $10.95, with a volume of 394.83K. It is down -3.44% in the last 24 hours and down -32.28% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$11.34

Open:

$11.19

24h Volume:

394.83K

Relative Volume:

0.96

Market Cap:

$215.91M

Revenue:

$244.06M

Net Income/Loss:

$87.01M

P/E Ratio:

6.0122

EPS:

1.8213

Net Cash Flow:

$105.95M

1W Performance:

-2.84%

1M Performance:

-32.28%

6M Performance:

-31.73%

1Y Performance:

-3.52%

1-Day Range:

$10.76

$11.41

1-Week Range:

$10.49

$11.41

52-Week Range:

$9.12

$22.55

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1118)

Industry

Biotechnology (620)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

Twitter

Next Earnings Date

2026-02-27

Latest SEC Filings

KROS's Discussions on Twitter

Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KROS Keros Therapeutics Inc	10.95	217.48M	244.06M	87.01M	105.95M	1.8213
VRTX Vertex Pharmaceuticals Inc	451.59	118.41B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	744.12	80.02B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	684.77	43.52B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	314.80	42.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	282.29	32.13B	5.36B	287.73M	924.18M	2.5229

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-16-24	Reiterated	Oppenheimer	Outperform
Dec-13-24	Reiterated	H.C. Wainwright	Buy
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy
Jun-25-24	Initiated	Oppenheimer	Outperform
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

10:06 AM

Targets Report: Is Keros Therapeutics Inc likely to announce a buyback2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn

10:06 AM

Mar 17, 2026

KROS: Does the Discounted Book Value Represent a Value Trap? - Bitget

Mar 17, 2026

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026 - The Globe and Mail

Mar 17, 2026

KROS Stock: Key Information on Rinvatercept for DMD - Bitget

Mar 17, 2026

KROS Pipeline Catalysts: DMD Phase II Progress and ALS Strategy for 2026 - Bitget

Mar 17, 2026

KROS: Is the Discount Book Value a Value Trap? - Yahoo Finance

Mar 17, 2026

Mar 16, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat

Mar 16, 2026

Mar 13, 2026

Keros Therapeutics (NASDAQ:KROS) Gains Market Attention In Nasdaq Index - Kalkine Media

Mar 13, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Mar 13, 2026

Mar 12, 2026

Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart.com

Mar 12, 2026

Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com

Mar 12, 2026

Mar 11, 2026

Keros Therapeutics (KROS) director submits initial Form 3 ownership - Stock Titan

Mar 11, 2026

Director adds Keros Therapeutics (NASDAQ: KROS) shares under 10b5-1 plan - Stock Titan

Mar 11, 2026

Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily

Mar 11, 2026

Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL) - The Globe and Mail

Mar 11, 2026

Mar 09, 2026

Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - Minichart

Mar 09, 2026

Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks

Mar 09, 2026

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget

Mar 09, 2026

Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times

Mar 09, 2026

Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView

Mar 09, 2026

Keros Therapeutics Presents Additional Clinical Data from - GlobeNewswire

Mar 09, 2026

Experimental drug boosts muscle and bone in early trial, eyed for DMD and ALS - Stock Titan

Mar 09, 2026

Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - MarketBeat

Mar 09, 2026

Mar 07, 2026

Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn

Mar 07, 2026

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail

Mar 07, 2026

Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat

Mar 07, 2026

Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn

Mar 07, 2026

Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Mar 07, 2026

Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir

Mar 07, 2026

Mar 06, 2026

Investment Review: Is now the right time to enter Keros Therapeutics IncChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Mar 06, 2026

Can Keros Therapeutics' Rinvatercept Distinguish Itself in the DMD Marketplace? - Bitget

Mar 06, 2026

What is HC Wainwright's Estimate for KROS FY2030 Earnings? - MarketBeat

Mar 06, 2026

Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility - TipRanks

Mar 06, 2026

Mar 05, 2026

Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat

Mar 05, 2026

Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus

Mar 05, 2026

Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq

Mar 05, 2026

Mar 04, 2026